| INTRODUCTION
The current understanding of type 1 diabetes mellitus (T1DM) is that autoimmune destruction of the β-cell leads to a permanent, insulinrequiring, disease. Accordingly, treatment is primarily focused on insulin replacement, with acute complications of hyper-and hypoglycemia being the primary barrier to tight glycemic control. T1DM has been associated with the presence of autoantibodies, including ICA-512, GAD-65, and IA-2; however, approximately 10% of patients diagnosed with T1DM are negative for autoimmune markers and 5% are persistently antibody-negative in follow-up evaluations. 1 The SEARCH for diabetes in youth study showed that 10% of 2291 subjects have non-autoimmune diabetes and suggested genetic mutations that affect β-cell function as a possible etiology of diabetes in these patients. 2 Accordingly, the ISPAD (International Society for Pediatric and Adolescent Diabetes) clinical practice guidelines now recommend genetic testing in very early onset and antibody-negative childhood diagnoses. 3 A higher incidence of HNF1A mutations and variants that are highly associated with type 2 diabetes, have been identified in the persistently antibody-negative group. 1 We and others have demonstrated that at least 1 form of insulin-deficient diabetes, neonatal diabetes mellitus (NDM), is primarily due to defects in the glucose metabolism and excitation-dependent insulin secretion pathway. [4] [5] [6] [7] [8] [9] [10] In such patients, β-cell mass is not initially lost, and insulin therapy is not necessarily appropriate. Indeed, most NDM patients who have mutations in 1 of the 2 subunits of the ATP † These authors contributed equally to this work. ‡ Present address: Department of Pediatrics, University of Virginia, Charlottesville, VA 22903.
sensitive K+ (K ATP ) channel (Kir6.2 or SUR1) will robustly and repeatedly respond to sulfonylureas, which circumvents the insulin secretory defect. 7, [11] [12] [13] [14] Restoring the insulin secretory response in patients who still
have functional yet silent β-cells not only improves glycemic control but also often results in a reduction in the incidence of hypoglycemia.
It is conceivable that our understanding of the mechanistic basis of the diabetes in some individuals carrying the diagnosis of T1DM is not correct, and that defects in the pathway of glucose-stimulated insulin secretion (GSIS) are at fault. The dramatic demonstration of sulfonylurea dependent insulin secretion in NDM, 11 as well as in carriers of HNF1A mutations 15 makes a compelling argument for further investigation of the potential action of these drugs in relevant groups of patients with diabetes. Sulfonylureas may provide not only a suitable tool for identification of such individuals but also a potentially appropriate therapy, as is clear in humans and mice with NDM. 4, [11] [12] [13] [14] 16, 17 The pathway of GSIS is complex and defects at any step could result in failure of insulin secretion 6, 18 . We hypothesize that some people diagnosed with T1DM, particularly those who are autoantibody negative, may actually suffer from defects in GSIS and still have viable β-cells that do not secrete in response to glucose, but will still secrete insulin in response to sulfonylureas. In this study, we therefore developed an approach to evaluate endogenous insulin secretion in response to glucose and sulfonylurea challenge in a cohort of patients previously diagnosed as type 1 diabetes. and was on both glyburide (sulfonylurea) and insulin therapies for diabetes management. Three subjects diagnosed with T1DM with positive autoantibodies were included as presumed negative controls (but see Section 3). Twelve subjects previously diagnosed with T1DM who had negative islet cell antibodies (ICA) and glutamic acid decarboxylase (GAD) antibody levels were included as test subjects.
| METHODS

| Subjects
| Sulfonylurea challenge
Three control subjects without diabetes (subjects C1, C2, and C3), 3 | RESULTS
| Parameter setting in control subjects
Controls C1, C2, and C3, all healthy subjects who had tested negative for ICA and GAD antibodies (Table 1) , showed C-peptide rising in response to glucose and rising again after glipizide ( Figure 1 ). A small increase in C-peptide levels was found in C1's response to 5 mg glipizide ( Figure 1A ), but there was a vigorous response in C2 and C3
given 15 or 40 mg glipizide, respectively, with corresponding hypoglycemia ( Figure 1B ,C). The rise in C-peptide after glipizide is in contrast to the continuing fall in insulin expected by 20 minutes after a single bolus dose of glucose. 22 Based on this result, a dose of 15 mg glipizide was chosen as sufficient to elicit a C-peptide response but minimize hypoglycemia in normal subjects, and was
given in initial studies in T1DM subjects. However, once it became with KCNJ11 gain-of-function mutations. 18 Sulfonylurea challenge elicited a greater increase in C-peptide levels, with a peak at 1.85 ng/mL, even as glucose levels decreased (Figure 2A ). Patient TNDM similarly showed a small increase in C-peptide after 20 g intravenous dextrose,
and a marked C-peptide release after 15 mg glipizide ( Figure 2B ).
Two of the antibody positive T1DM subjects (Ab+T1DM:1 and 2) ( Table 2) showed the anticipated failure to increase C-peptide levels in response to either dextrose infusion or sulfonylurea injection ( Figure 2C,D) . However, Ab+T1DM:3 showed a small C-peptide response to dextrose, and an unexpectedly higher increase in Cpeptide levels after a single dose of 40 mg glipizide ( Figure 2E ). Ab +T1DM:3 was a 20-year-old woman diagnosed with type 1 diabetes at age 15 when she presented with a hemoglobin A1c >14% without ketoacidosis with positive GAD-65 antibodies (10 U/mL) and ICA-512 antibodies (3.2 U/mL). She was poorly controlled on subcutaneous insulin and presented twice with moderate ketonuria, once after apparently taking little or no insulin for several months. She became pregnant soon after this study result became available and is currently lost to follow up.
| Sulfonylurea challenge in antibody-negative T1DM subjects
A total of 29 of the additional 41 diagnosed T1DM subjects tested positive for at least 1 of the 3 tested antibodies and were not studied further (Ab screen only, Table 1 ). The 12 antibody-negative T1DM subjects (Ab−T1DM, Table 2 ) underwent the glucose and sulfonylurea challenge. Of these, 11 also showed no increase in C-peptide levels after either 20 g intravenous dextrose or glipizide ( Figure 3A) . Interestingly, however, 1 Ab−T1DM subject (Ab−T1DM:12) did respond preferentially to glipizide ( Figure 3B ). Ab−T1DM:12 was a 16-yearold boy who presented at age 14 with diabetes with hemoglobin A1c of 11.5%, mild acidosis (pH of 7.32), and has maintained good control on subcutaneous insulin. GAD-65 and ICA-512 antibody levels were undetectable ( Table 1) . 
| Sulfonylurea challenge as a clinical test?
Clinical response to sulfonylureas varies in type 2 diabetes, and even in neonatal diabetes with the same underlying genetic mutations in the sulfonylurea target K ATP channel genes, ABCC8 and KCNJ11.
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We found low glucose-stimulated C-peptide production in most subjects diagnosed with T1DM, consistent with the presumption of near complete loss of β-cells, whether antibodies were positive or negative. However, 2 of 12 T1DM subjects, 1 antibody positive and 1 antibody negative, responded robustly to a single dose of glipizide even though both subjects had a poor C-peptide response to glucose infusion (Figures 2 and 3 ). This differential response to glucose vs sulfonylurea suggests that these subjects are not simply typical T1DM
patients with residual β-cells in a prolonged "honeymoon" period.
Instead, it suggests they are patients with a defect in GSIS that can Analysis of sulfonylurea (SU) responsivity vs glucose responsivity. A, Method of analysis illustrated for data from control subject 1. C-Peptide response to glucose was assumed to decline exponentially from initial peak to baseline (mean of 4 measurements before dextrose injection). The area under the resultant curve (AUCDex, blue) was then subtracted from the area under the curve (up to 200 minutes) to estimate the AUCGlip. B, AUCGlip (above) and the ratio of AUCGlip/AUCDex (below). For healthy control subjects, permanent neonatal diabetes mellitus (PNDM) and TNDM, as well as the 2 responder type 1 diabetes mellitus (T1DM) patients (Ab+T1DM:3, Ab−T1DM:12), AUCGlip was >50 ng/mL/min, but was <10 ng/mL/min, for all non-responder Ab+T1DM and Ab−T1DM patients. AUCGlip/AUCDex was <3 for healthy control subjects, but was >6 for responder NDM controls and test subjects sulfonylurea and to glucose. Figure 4 shows a proposed analysis. The C-peptide area under the curve (AUC) in response to dextrose (AUCDex) can be estimated by assuming an exponential decay following injection, and then subtracted from the total AUC to obtain the glipizide response (AUCGlip, Figure 4A ). Alternatively, administering the glucose challenge and the drug challenge on 2 separate occasions would allow the glucose AUC to be obtained directly. Using the first approach, we show that the AUCGlip for all responders and positive control subjects is in the range 50 to 500 ng/L/min, but is below the detection limit of~10 ng/mL/min for the non-responders ( Figure 4B, above) . Notably, the ratio AUCGlip/AUCDex ( Figure 4B , below) does appear to distinguish responders (AUCGlip/AUCDex >6) from control subjects who respond to both glucose and SU (AUCGlip/AUCDex <2).
The study found a higher number of antibody-negative subjects than naively expected. We suggest that is likely due to the antibody screens not having being made at the time of diagnosis. Although our subject group is very small the finding of sulfonylurea responsivity in both 1 autoantibody-positive and 1 autoantibody-negative patient is suggestive that positive antibody testing may not necessarily rule out alternative causes. When genetic testing is obtained in the clinical setting, typically only individual candidate genes are examined, and any novel genetic causes will be missed. Thus any individuals without a known genetic mutation would miss the opportunity to explore sulfonylureas as a therapeutic option. As the interpretation of genetic testing is best correlated with clinical status, the protocol we present could provide additional information to clinical providers and to patients regarding residual β-cell function and stimulatory C-peptide response.
We would note that a robust C-peptide response to sulfonylurea in this challenge test still does not necessarily mean that the subject has a form of diabetes that will have a good outcome with long-term sulfonylurea therapy, and clearly far more extensive follow-up studies are needed.
| Conclusions
In conclusion, the sulfonylurea challenge test that we present is a promising, relatively low-cost, low-risk method of identifying which patients with newly diagnosed diabetes may have a specific defect in metabolism-excitation-secretion coupling rather than autoimmune T1DM. Such patients may then benefit from further genetic analysis for known and unknown causes of diabetes. The test could potentially identify those who could benefit from sulfonylurea therapy. The sentinel example of NDM caused by mutations in the K ATP channel has proven the principle that even long-standing diabetes with such defects, who otherwise exhibit no evidence of C-peptide response to glucose can respond robustly to sulfonylureas. 7, 11, 14 The ability of sulfonylurea drugs to stimulate C-peptide production has not been well characterized in broader cohorts of patients diagnosed with T1DM. The protocol we present allows objective measurement of Cpeptide response to sulfonylurea as an assessment of β-cell function in the identification of sulfonylurea-responsive subjects with diabetes. The feasibility we demonstrate, together with positive findings in even such a small cohort, therefore warrants more extensive implementation to determine the usefulness of the test, both as a potential guide to the choice of most appropriate therapy and genetic testing strategies for patients, as well as for identification of novel genetic causes of diabetes.
